Induced Pluripotent Stem Cells: Generation Methods and a New Perspective in COVID-19 Research

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2023 Feb 3

PMID 36733338

Authors

Zahra Karami

Sharif Moradi

Akram Eidi

Masoud Soleimani

Arefeh Jafarian

Affiliations

Soon will be listed here.

Abstract

Induced pluripotent stem cells (iPSCs) exhibit an unlimited ability to self-renew and produce various differentiated cell types, thereby creating high hopes for both scientists and patients as a great tool for basic research as well as for regenerative medicine purposes. The availability and safety of iPSCs for therapeutic purposes require safe and highly efficient methods for production of these cells. Different methods have been used to produce iPSCs, each of which has advantages and disadvantages. Studying these methods would be very helpful in developing an easy, safe, and efficient method for the generation of iPSCs. Since iPSCs can be generated from somatic cells, they can be considered as valuable cellular resources available for important research needs and various therapeutic purposes. Coronavirus disease 2019 (COVID-19) is a disease that has endangered numerous human lives worldwide and currently has no definitive cure. Therefore, researchers have been rigorously studying and examining all aspects of COVID-19 and potential treatment modalities and various drugs in order to enable the treatment, control, and prevention of COVID-19. iPSCs have become one of the most attractive and promising tools in this field by providing the ability to study COVID-19 and the effectiveness of drugs on this disease outside the human body. In this study, we discuss the different methods of generation of iPSCs as well as their respective advantages and disadvantages. We also present recent applications of iPSCs in the study and treatment of COVID-19.

Citing Articles

Human iPSC Reprogramming Success: The Impact of Approaches and Source Materials.

Pozner T, Grandizio C, Mitchell M, Turan N, Scheinfeldt L Stem Cells Int. 2025; 2025:2223645.

PMID: 39850337 PMC: 11756937. DOI: 10.1155/sci/2223645.

Efficient generation of human induced pluripotent stem cells from urine samples of patients with Fragile X syndrome.

Dionne O, Sabatie S, Fortin F, Corbin F, Laurent B Front Cell Dev Biol. 2024; 12:1489190.

PMID: 39650724 PMC: 11621072. DOI: 10.3389/fcell.2024.1489190.

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.

Alidadi M, Barzgar H, Zaman M, Paevskaya O, Metanat Y, Khodabandehloo E Front Cell Dev Biol. 2024; 12:1491282.

PMID: 39624236 PMC: 11609223. DOI: 10.3389/fcell.2024.1491282.

Revolutionizing medicine: recent developments and future prospects in stem-cell therapy.

Hussen B, Hussen B, Taheri M, Yashooa R, Abdullah G, Abdullah S Int J Surg. 2024; 110(12):8002-8024.

PMID: 39497543 PMC: 11634165. DOI: 10.1097/JS9.0000000000002109.

Generation of induced pluripotent stem cells from the Asian bats.

Lee Y, Koo O, Saadeldin I Int J Vet Sci Med. 2024; 12(1):81-90.

PMID: 39139714 PMC: 11321101. DOI: 10.1080/23144599.2024.2384835.

References

Yamoah M, Moshref M, Sharma J, Chen W, Ledford H, Lee J . Highly efficient transfection of human induced pluripotent stem cells using magnetic nanoparticles. Int J Nanomedicine. 2018; 13:6073-6078. PMC: 6179720. DOI: 10.2147/IJN.S172254. View

Shi Y, Inoue H, Wu J, Yamanaka S . Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2016; 16(2):115-130. PMC: 6416143. DOI: 10.1038/nrd.2016.245. View

Han F, Liu Y, Huang J, Zhang X, Wei C . Current Approaches and Molecular Mechanisms for Directly Reprogramming Fibroblasts Into Neurons and Dopamine Neurons. Front Aging Neurosci. 2021; 13:738529. PMC: 8515543. DOI: 10.3389/fnagi.2021.738529. View

Esmail S, Danter W . Viral pandemic preparedness: A pluripotent stem cell-based machine-learning platform for simulating SARS-CoV-2 infection to enable drug discovery and repurposing. Stem Cells Transl Med. 2020; 10(2):239-250. PMC: 7537153. DOI: 10.1002/sctm.20-0181. View

Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer R, Stahl M . Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020; 181(4):905-913.e7. PMC: 7181998. DOI: 10.1016/j.cell.2020.04.004. View

Masuda S, Wu J, Hishida T, Pandian G, Sugiyama H, Izpisua Belmonte J . Chemically induced pluripotent stem cells (CiPSCs): a transgene-free approach. J Mol Cell Biol. 2013; 5(5):354-5. DOI: 10.1093/jmcb/mjt034. View

Cuevas-Gonzalez M, Garcia-Perez A, Gonzalez-Aragon Pineda A, Espinosa-Cristobal L, Donohue-Cornejo A, Tovar-Carrillo K . Stem Cells as a Model of Study of SARS-CoV-2 and COVID-19: A Systematic Review of the Literature. Biomed Res Int. 2021; 2021:9915927. PMC: 8390136. DOI: 10.1155/2021/9915927. View

Ebrahimi B . Reprogramming barriers and enhancers: strategies to enhance the efficiency and kinetics of induced pluripotency. Cell Regen. 2015; 4:10. PMC: 4642739. DOI: 10.1186/s13619-015-0024-9. View

Nishimura K, Ohtaka M, Takada H, Kurisaki A, Tran N, Tran Y . Simple and effective generation of transgene-free induced pluripotent stem cells using an auto-erasable Sendai virus vector responding to microRNA-302. Stem Cell Res. 2017; 23:13-19. DOI: 10.1016/j.scr.2017.06.011. View

10.

Liu G, David B, Trawczynski M, Fessler R . Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. Stem Cell Rev Rep. 2019; 16(1):3-32. PMC: 6987053. DOI: 10.1007/s12015-019-09935-x. View

11.

Elhabyan A, Elyaacoub S, Sanad E, Abukhadra A, Elhabyan A, Dinu V . The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review. Virus Res. 2020; 289:198163. PMC: 7480444. DOI: 10.1016/j.virusres.2020.198163. View

12.

Ramani A, Muller L, Ostermann P, Gabriel E, Abida-Islam P, Muller-Schiffmann A . SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 2020; 39(20):e106230. PMC: 7560208. DOI: 10.15252/embj.2020106230. View

13.

Martin U . Therapeutic Application of Pluripotent Stem Cells: Challenges and Risks. Front Med (Lausanne). 2018; 4:229. PMC: 5735065. DOI: 10.3389/fmed.2017.00229. View

14.

Ahmadi A, Moradi S . In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection. Sci Rep. 2021; 11(1):10271. PMC: 8119475. DOI: 10.1038/s41598-021-89605-6. View

15.

Wang T, Chen K, Zeng X, Yang J, Wu Y, Shi X . The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell. 2011; 9(6):575-87. DOI: 10.1016/j.stem.2011.10.005. View

16.

Haridhasapavalan K, Raina K, Dey C, Adhikari P, Thummer R . An Insight into Reprogramming Barriers to iPSC Generation. Stem Cell Rev Rep. 2019; 16(1):56-81. DOI: 10.1007/s12015-019-09931-1. View

17.

Ohi Y, Qin H, Hong C, Blouin L, Polo J, Guo T . Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol. 2011; 13(5):541-9. PMC: 3987913. DOI: 10.1038/ncb2239. View

18.

Stadtfeld M, Hochedlinger K . Induced pluripotency: history, mechanisms, and applications. Genes Dev. 2010; 24(20):2239-63. PMC: 2956203. DOI: 10.1101/gad.1963910. View

19.

Shen C, Peng L, Zhang Y, Zeng H, Yu H, Jin L . Reference Genes for Expression Analyses by qRT-PCR in (Lepidoptera: Gelechiidae). Insects. 2022; 13(2). PMC: 8879603. DOI: 10.3390/insects13020140. View

20.

Schlaeger T . Nonintegrating Human Somatic Cell Reprogramming Methods. Adv Biochem Eng Biotechnol. 2017; 163:1-21. DOI: 10.1007/10_2017_29. View